Rachel F. Lane
Analyste en capital-investissement chez Versant Venture Management LLC
Profil
Rachel F.
Lane is currently a Principal at Versant Venture Management LLC since 2020.
Prior to this, she worked as an Associate Director of Scientific Affairs at Alzheimers Drug Discovery Foundation from 2011 to 2014, a Principal at Icahn School of Medicine at Mount Sinai from 2008 to 2011, and an Equity Research Associate at H.
C.
Wainwright & Co. LLC from 2014 to 2016.
Dr. Lane received her undergraduate degree from Sheffield Hallam University and her doctorate degree from The University of Sheffield in 2008.
Postes actifs de Rachel F. Lane
| Sociétés | Poste | Début |
|---|---|---|
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Analyste en capital-investissement | 01/06/2020 |
Anciens postes connus de Rachel F. Lane
| Sociétés | Poste | Fin |
|---|---|---|
H. C. Wainwright & Co. LLC
 H. C. Wainwright & Co. LLC Investment Banks/BrokersFinance H. C. Wainwright & Co. LLC (H. C. Wainwright) is a full-service broker/dealer headquartered in New York City. The firm was founded in 1868 and is a subsidiary of HCWHC, Inc. H. C. Wainwright delivers industry insights and real-time execution to both public and private small and middle-sized global emerging market companies. With a focus on identifying buyers and sellers in illiquid and difficult to trade equities, the firm specializes in block trading and providing liquidity in these securities with as little market impact as possible. | Analyst-Equity | 01/12/2016 |
Alzheimers Drug Discovery Foundation
 Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | Corporate Officer/Principal | 01/11/2014 |
| Icahn School of Medicine at Mount Sinai | Corporate Officer/Principal | 01/08/2011 |
Formation de Rachel F. Lane
| The University of Sheffield | Doctorate Degree |
| Sheffield Hallam University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
H. C. Wainwright & Co. LLC
H. C. Wainwright & Co. LLC Investment Banks/BrokersFinance H. C. Wainwright & Co. LLC (H. C. Wainwright) is a full-service broker/dealer headquartered in New York City. The firm was founded in 1868 and is a subsidiary of HCWHC, Inc. H. C. Wainwright delivers industry insights and real-time execution to both public and private small and middle-sized global emerging market companies. With a focus on identifying buyers and sellers in illiquid and difficult to trade equities, the firm specializes in block trading and providing liquidity in these securities with as little market impact as possible. | Finance |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | Health Technology |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |